The study highlights the enormous potential for improving appropriate prescription of anti-malarials in pharmacies and preventing unnecessary use of artemisinin combination therapy (ACT).
artemisinin combination therapy (ACT)
The marked variability in the disposition of different forms of ACT remained largely unexplained by the available covariates.
These compounds provide a new class of so desperately needed anti-malarial drug. Despite a short half-life and moderate oral bioavailability, this class of compounds was able to cure malaria in mice at very low dosages implicating extremely active metabolites.
Drugs are primary weapons for reducing malaria in human populations.
The evidence shows that there is no short-cut to investing in training and supervision of providers, or in treating malaria within a public health context rather than as a separate disease.
Concerns for emergence of parasite resistance due the use of artemisinin-naphthoquine as single dose regimen is likely to compromise the usefulness of this potentially important combination treatment.
The study was successful in quantifying and characterizing known reactions and has benchmarking value.
The parasite population retains high population diversity despite hypo-endemic transmission with retention, but decrease in the chloroquine-resistant allele and Pfmdr1 resistant alleles in the Chittagong Hill Tracts of Bangladesh.
In this position paper, the European Society for Clinical Microbiology and Infectious Diseases, Study Group on Clinical Parasitology, summarizes main issues regarding the management of imported malaria cases.
The AMFm led to large increases in availability of low priced ACT in Tanzania, with no significant variation in availability based on remoteness.